Talabostat mesylate - CAS 150080-09-4
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Talabostat mesylate
Catalog Number:
150080-09-4
Synonyms:
PT-100; D05989; ValboroPro; [(2R)-1-[(2S)-2-Amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid mesylate
CAS Number:
150080-09-4
Description:
Talabostat mesylate is the orally bioavailable mesylate salt of an amino boronic dipeptide with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell- dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.
Molecular Weight:
310.17
Molecular Formula:
C10H23BN2O6S
Quantity:
Milligrams-Grams
Quality Standard:
Enterprise Standard
COA:
Certificate of Analysis-Talabostat mesylate 150080-09-4 B14QT0822  
MSDS:
Inquire
Targets:
DPP4
Current Developer:
Point Therapeutics
Chemical Structure
CAS 150080-09-4 Talabostat mesylate

Related DPP4 Products


CAS 361442-04-8 Saxagliptin

Saxagliptin
(CAS: 361442-04-8)

Saxagliptin is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is oral...

ASP-4000 hydrochoride
(CAS: 851389-35-0)

ASP-4000 is a dipeptidyl peptidase 4 (DPP) inhibitor. It has antihyperglycemic activity.

CAS 654671-77-9 Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate
(CAS: 654671-77-9)

Sitagliptin phosphate is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts. It is used either alone or in combination with other oral anti...

CAS 850649-62-6 ALOGLIPTIN BENZOATE

ALOGLIPTIN BENZOATE
(CAS: 850649-62-6)

Alogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

CAS 654671-78-0 Sitagliptin phosphate

Sitagliptin phosphate
(CAS: 654671-78-0)

Sitagliptin phosphate is a potent inhibitor of DPP4 in Caco-2 cell extracts.

CAS 945667-22-1 Saxagliptin hydrate

Saxagliptin hydrate
(CAS: 945667-22-1)

Saxagliptin hydrate is a selective and reversible DPP4 inhibitor. It demonstrates greater specificity for DPP4 than for either the DPP8 or DPP9 enzymes. It redu...

CAS 150080-09-4 Talabostat mesylate

Talabostat mesylate
(CAS: 150080-09-4)

Talabostat mesylate is the orally bioavailable mesylate salt of an amino boronic dipeptide with antineoplastic and hematopoiesis- stimulating activities. By cle...

CAS 850649-61-5 Alogliptin

Alogliptin
(CAS: 850649-61-5)

Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

CAS 760937-92-6 Teneligliptin

Teneligliptin
(CAS: 760937-92-6)

Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human recombinant ...

CAS 865759-25-7 Trelagliptin

Trelagliptin
(CAS: 865759-25-7)

Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with...

Evogliptin
(CAS: 1222102-29-5)

This active molecular is a selective dipeptidyl peptidase 4 (DPP4) inhibitor under the development of Dong-A. Evogliptin improves insulin resistance and delays ...

CAS 1029877-94-8 Trelagliptin succinate

Trelagliptin succinate
(CAS: 1029877-94-8)

Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).

CAS 668270-12-0 Linagliptin

Linagliptin
(CAS: 668270-12-0)

A novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.

CAS 852329-66-9 Dutogliptin

Dutogliptin
(CAS: 852329-66-9)

Dutogliptin is a selective and orally active DPP4 inhibitor. It can improve glycaemic control in patients with type 2 diabetes. But phase III clinical trials fo...

CAS 1186426-66-3 DBPR108

DBPR108
(CAS: 1186426-66-3)

DBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including ...

ASP-8497 free base
(CAS: 651055-25-3)

ASP-8497 free base is a long-acting and potent DPP-IV inhibitor. It improves glucose tolerance through glucose-dependent insulinotropic action via elevation of ...

CAS 274901-16-5 Vildagliptin

Vildagliptin
(CAS: 274901-16-5)

Glyptins are class of oral anti-hyperglycemic agents that inhibit dipeptidyl peptidase 4 (DPP-4), which can act as a serine exopeptidase. ASide from there use i...

CAS 906093-29-6 Teneligliptin hydrobromide

Teneligliptin hydrobromide
(CAS: 906093-29-6)

Teneligliptin hydrobromide is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human...

CAS 869490-23-3 Gosogliptin

Gosogliptin
(CAS: 869490-23-3)

Gosogliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor. But no development was reported about Phase-II for Type-2 diabetes mellitus.

CAS 486460-32-6 Sitagliptin

Sitagliptin
(CAS: 486460-32-6)

Sitagliptin(MK 0431) is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.

Reference Reading


1.Gateways to clinical trials.
Bayes M1, Rabasseda X, Prous JR. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 5-Methyltetrahydrofolate, 9-aminocamptothecin; AdPEDF.11, AE-37, albumin interferon alfa, alicaforsen sodium, alvocidib hydrochloride, AMG-706, arginine butyrate, avanafil, axitinib, azimilide hydrochloride; BAY-579352, belagenpumatucel-L, beta-lapachone, BHT-3009, BIBW-2992, bremelanotide, BX-471; Casopitant mesylate, cediranib, certolizumab pegol, CH-1504, ChimeriVax-West Nile, clofazimine, CpG-7909, curcumin, Cypher; Dapoxetine hydrochloride, darusentan, diflomotecan, D-methionine, dnaJP1, D-serine, DTPw-HB Hib-MenAC, DTPw-HepB-Hib; E-7010, ecogramostim, edodekin alfa, EGFRvlll peptide vaccine, elcometrine, elcometrine/ethinylestradiol, elsilimomab, enrasentan, ertumaxomab, etalocib sodium, exisulind; Fenretinide, fesoterodine, fingolimod hydrochloride, fontolizumab; Gefitinib, gemtuzumab ozogamicin, ghrelin (human), GV-1001; HTU-PA, human papillomavirus vaccine; Indacaterol, indiplon, interleukin-21, intranasal insulin, irinotecan hydrochloride/floxuridine, ISIS-301012, ispinesib mesylate, ixabepilone; K562/GM-CSF; Lapatinib, L-BLP-25, linezolid, liposome encapsulated paclitaxel, LY-2124275; MC-1, MC-1/lisinopril, MDX-066, melanoma vaccine, MMR-V, multivalent (ACYW) meningitis vaccine; Nilotinib, nobori, nociceptin; Oblimersen sodium, orbofiban acetate, ospemifene; Paliperidone, panitumumab, PEG-filgrastim, PEGylated interferon alfacon-1, perflubutane, pertuzumab, phenserine tartrate, phVEGF-A165, pleconaril, prasugrel, prednisolone sodium metasulfobenzoate; R-411, recombinant malaria vaccine, rhGM-CSF, roflumilast, romidepsin, ruboxistaurin mesilate hydrate; Sirolimus-eluting stent, SR-4554, St.
2.Gateways to clinical trials.
Bayés M1, Rabasseda X, Prous JR. Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Intergrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 249553, 2-Methoxyestradiol; Abatacept, Adalimumab, Adefovir dipivoxil, Agalsidase beta, Albinterferon alfa-2b, Aliskiren fumarate, Alovudine, Amdoxovir, Amlodipine besylate/atorvastatin calcium, Amrubicin hydrochloride, Anakinra, AQ-13, Aripiprazole, AS-1404, Asoprisnil, Atacicept, Atrasentan; Belimumab, Bevacizumab, Bortezomib, Bosentan, Botulinum toxin type B, Brivaracetam; Catumaxomab, Cediranib, Cetuximab, cG250, Ciclesonide, Cinacalcet hydrochloride, Curcumin, Cypher; Darbepoetin alfa, Denosumab, Dihydrexidine; Eicosapentaenoic acid/docosahexaenoic acid, Entecavir, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe; Febuxostat, Fenspiride hydrochloride, Fondaparinux sodium; Gefitinib, Ghrelin (human), GSK-1562902A; HSV-tk/GCV; Iclaprim, Imatinib mesylate, Imexon, Indacaterol, Insulinotropin, ISIS-112989; L-Alanosine, Lapatinib ditosylate, Laropiprant; Methoxy polyethylene glycol-epoetin-beta, Mipomersen sodium, Motexafin gadolinium; Natalizumab, Nimotuzumab; OSC, Ozarelix; PACAP-38, Paclitaxel nanoparticles, Parathyroid Hormone-Related Protein-(1-36), Pasireotide, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pertuzumab, Picoplatin, Pimecrolimus, Pitavastatin calcium, Plitidepsin; Ranelic acid distrontium salt, Ranolazine, Recombinant human relaxin H2, Regadenoson, RFB4(dsFv)-PE38, RO-3300074, Rosuvastatin calcium; SIR-Spheres, Solifenacin succinate, Sorafenib, Sunitinib malate; Tadalafil, Talabostat, Taribavirin hydrochloride, Taxus, Temsirolimus, Teriparatide, Tiotropium bromide, Tipifarnib, Tirapazamine, Tocilizumab; UCN-01, Ularitide, Uracil, Ustekinumab; V-260, Vandetanib, Vatalanib succinate, Vernakalant hydrochloride, Vorinostat; YM-155; Zileuton, Zoledronic acid monohydrate.